AU607012B2 - Agents for treating high blood pressure and cardiac insufficiency - Google Patents
Agents for treating high blood pressure and cardiac insufficiency Download PDFInfo
- Publication number
- AU607012B2 AU607012B2 AU24438/88A AU2443888A AU607012B2 AU 607012 B2 AU607012 B2 AU 607012B2 AU 24438/88 A AU24438/88 A AU 24438/88A AU 2443888 A AU2443888 A AU 2443888A AU 607012 B2 AU607012 B2 AU 607012B2
- Authority
- AU
- Australia
- Prior art keywords
- blood pressure
- group
- agents
- tho
- cardiac insufficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 206010020772 Hypertension Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000002253 acid Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 125000000217 alkyl group Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- -1 C 1 4 aikoxy Chemical group 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- ZRNKXJHEQKMWCH-UHFFFAOYSA-N 3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one;hydron;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCN(C)CCCN1C(=O)CC2=CC(OC)=C(OC)C=C2CC1 ZRNKXJHEQKMWCH-UHFFFAOYSA-N 0.000 description 1
- 241001377084 Actites Species 0.000 description 1
- 102100028633 Cdc42-interacting protein 4 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101100001674 Emericella variicolor andI gene Proteins 0.000 description 1
- 101100213135 Escherichia coli (strain K12) ydaQ gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000766830 Homo sapiens Cdc42-interacting protein 4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282337 Nasua nasua Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101150011375 Tab2 gene Proteins 0.000 description 1
- 101000857680 Xenopus laevis Runt-related transcription factor 1 Proteins 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Electrotherapy Devices (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873736866 DE3736866A1 (de) | 1987-10-30 | 1987-10-30 | Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz |
| DE3736866 | 1987-10-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2443888A AU2443888A (en) | 1989-05-04 |
| AU607012B2 true AU607012B2 (en) | 1991-02-21 |
Family
ID=6339463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU24438/88A Ceased AU607012B2 (en) | 1987-10-30 | 1988-10-28 | Agents for treating high blood pressure and cardiac insufficiency |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5516773A (enExample) |
| EP (2) | EP0471388B1 (enExample) |
| JP (1) | JP2665357B2 (enExample) |
| KR (1) | KR960011240B1 (enExample) |
| AT (1) | ATE91418T1 (enExample) |
| AU (1) | AU607012B2 (enExample) |
| DE (2) | DE3736866A1 (enExample) |
| DK (1) | DK603688A (enExample) |
| HK (1) | HK175896A (enExample) |
| HU (1) | HU203282B (enExample) |
| ZA (1) | ZA888090B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| ES2211846T3 (es) * | 2002-07-25 | 2004-07-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Uso de cilobradina o sus sales farmaceuticamente aceptables para el tratamiento o la prevencion de la insuficiencia cardiaca. |
| US20040138306A1 (en) * | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| EP1762179A1 (en) | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Method for improving diagnostic quality in echocardiography |
| FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
| AU2012296925A1 (en) * | 2011-08-12 | 2014-02-06 | Boehringer Ingelheim Vetmedica Gmbh | Taste masked pharmaceutical composition |
| EP2953612A1 (en) | 2013-02-11 | 2015-12-16 | Boehringer Ingelheim Vetmedica GmbH | Kit-of-parts |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0065229A1 (de) * | 1981-05-19 | 1982-11-24 | Dr. Karl Thomae GmbH | Neue Benzazepinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2639718C2 (de) * | 1976-09-03 | 1987-03-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | 1-[6,7-Dimethoxy-3,4-dihydro-2H-isochinolin-1-on-2-yl]-3-[N-methyl-N-(2-(3,4-dimethoxy-phenyl)-äthyl)-amino]-propan, dessen physiologisch verträgliche Säureadditionssalze und diese Verbindungen enthaltende Arzneimittel |
| US4490369A (en) * | 1981-05-19 | 1984-12-25 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Benzazepine derivatives, their pharmaceutical compositions and method of use |
-
1987
- 1987-10-30 DE DE19873736866 patent/DE3736866A1/de not_active Withdrawn
-
1988
- 1988-10-15 EP EP91118481A patent/EP0471388B1/de not_active Expired - Lifetime
- 1988-10-15 DE DE91118481T patent/DE3882381D1/de not_active Expired - Fee Related
- 1988-10-15 EP EP19880117181 patent/EP0313945A3/de not_active Withdrawn
- 1988-10-28 HU HU885641A patent/HU203282B/hu not_active IP Right Cessation
- 1988-10-28 JP JP63272855A patent/JP2665357B2/ja not_active Expired - Fee Related
- 1988-10-28 DK DK603688A patent/DK603688A/da not_active Application Discontinuation
- 1988-10-28 KR KR1019880014066A patent/KR960011240B1/ko not_active Expired - Fee Related
- 1988-10-28 ZA ZA888090A patent/ZA888090B/xx unknown
- 1988-10-28 AU AU24438/88A patent/AU607012B2/en not_active Ceased
-
1991
- 1991-10-30 AT AT91118481T patent/ATE91418T1/de not_active IP Right Cessation
-
1993
- 1993-08-09 US US08/104,224 patent/US5516773A/en not_active Expired - Lifetime
-
1996
- 1996-09-19 HK HK175896A patent/HK175896A/xx not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0065229A1 (de) * | 1981-05-19 | 1982-11-24 | Dr. Karl Thomae GmbH | Neue Benzazepinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU551509B2 (en) * | 1981-05-19 | 1986-05-01 | Dr. Karl Thomae Gmbh | Benzazepine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3736866A1 (de) | 1989-05-11 |
| HU203282B (en) | 1991-07-29 |
| ZA888090B (en) | 1990-07-25 |
| ATE91418T1 (de) | 1993-07-15 |
| EP0471388B1 (de) | 1993-07-14 |
| EP0313945A2 (de) | 1989-05-03 |
| HUT48464A (en) | 1989-06-28 |
| HK175896A (en) | 1996-09-27 |
| EP0313945A3 (de) | 1990-12-05 |
| DK603688A (da) | 1989-05-01 |
| KR890006234A (ko) | 1989-06-12 |
| US5516773A (en) | 1996-05-14 |
| AU2443888A (en) | 1989-05-04 |
| KR960011240B1 (ko) | 1996-08-21 |
| EP0471388A2 (de) | 1992-02-19 |
| DE3882381D1 (enExample) | 1993-08-19 |
| DK603688D0 (da) | 1988-10-28 |
| JP2665357B2 (ja) | 1997-10-22 |
| EP0471388A3 (de) | 1992-03-11 |
| JPH02138123A (ja) | 1990-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO1992021345A1 (ja) | 抗腫瘍効果増強のための及び腫瘍治療のための組成物 | |
| CN1528315A (zh) | 治疗糖皮质素功能失调相关性精神病的方法 | |
| EP1881832A2 (en) | Use of flibanserin in the treatment of chronic pain | |
| WO1994012184A1 (en) | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis | |
| AU607012B2 (en) | Agents for treating high blood pressure and cardiac insufficiency | |
| EP2129400A2 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| JP2018509474A (ja) | インダン酢酸誘導体を用いる肝疾患の治療方法 | |
| US6451813B1 (en) | Treatment of gastroparesis in certain patient groups | |
| WO2010128258A1 (fr) | Combinaison antitumorale comprenant le cabazitaxel et la capecitabine | |
| US20090036527A1 (en) | Therapeutic Application Of Leonurine In Treating Cardiomyopathy | |
| US20060223811A1 (en) | Triglycerine depressant composition | |
| US7041677B2 (en) | Use of monochloroflosequinan in the treatment of sexual dysfunction | |
| JPH11269171A (ja) | ５―（１，２―ジチオラン―３―イル―）吉草酸（α―リポ酸）またはその生理学的に許容しうる塩を有効成分とする脂肪代謝障害治療剤 | |
| Urdang | Bantam Medical Dictionary | |
| JPS5823618A (ja) | 精神分裂症を治療する組成物 | |
| DE60107559T2 (de) | Kombination von carboxyalkylethern mit antihypertensiva und pharmazeutische verwendung | |
| DE60119868T2 (de) | Verwendung eines Östrogenagonisten zum Verbessern der vaskulären Gesundheit | |
| US20040242676A1 (en) | Method of mitigating the adverse effects of IL-2 | |
| JPS6277328A (ja) | 循環改善剤 | |
| US20070093519A1 (en) | Anti-emetic uses of cannabinoid analogs | |
| JP3533491B2 (ja) | 血管新生阻害剤 | |
| CN100378064C (zh) | 苯环壬酯的活性代谢产物及其医药用途 | |
| US4786634A (en) | Method for treating arteriosclerosis | |
| WO2002058703A2 (en) | The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers | |
| CN116650490A (zh) | 化合物mt-1207在降低尿酸方面的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |